Animal models of Huntington's disease: From basic research on neuronal death to assessment of new therapeutic strategies

Functional Neurology

Volumn 15, Issue 4, 2000, Pages 239-251

  Brouillet, E ^a  

^a DIF   (France)

Author keywords

Animal models; Apoptosis; Excitotoxicity; Huntington's disease; Mitochondria; Therapy

Indexed keywords

3 NITROPROPIONIC ACID; CILIARY NEUROTROPHIC FACTOR; CREATINE; GLUTAMATE RECEPTOR ANTAGONIST; HUNTINGTIN; NITRIC OXIDE SYNTHASE INHIBITOR; RILUZOLE; SCAVENGER; SUCCINATE DEHYDROGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; BRAIN DEATH; BRAIN MITOCHONDRION; CLINICAL FEATURE; CONFERENCE PAPER; HUMAN; HUNTINGTON CHOREA; KNOCKOUT MOUSE; MEDICAL RESEARCH; NEURITIS; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIMATE;

ANIMALS; APOPTOSIS; ATROPHY; CEREBRAL CORTEX; CILIARY NEUROTROPHIC FACTOR; COGNITION DISORDERS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; HUNTINGTON DISEASE; MACACA; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MITOCHONDRIA; MOVEMENT DISORDERS; NERVE DEGENERATION; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; NUCLEAR PROTEINS; PAPIO; POINT MUTATION; RATS; RECEPTORS, N-METHYL-D-ASPARTATE; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 0034490994     PISSN: 03935264     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (50)

1. The gait abnormality of Huntington's disease
2. Frontal-subcortical circuits and human behavior
3. Executive and mnemonic functions in early Huntington's disease
4. Neuropathological classification of Huntington's disease
5. Patterns of cell loss in Huntington's disease
6. Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease
7. Proliferative and degenerative changes in striatal spiny-neurons in Huntington's disease: A combined study using the section-Golgi method and calbindin D28k immunochemistry
8. Morphometric demonstration of atrophic changes in the cerebral cortex, white matter and neostriatum in Huntington's disease
9. Morphometric analysis of the prefrontal cortex in Huntington's disease
10. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes
11. Toward understanding the molecular pathology of Huntington's disease
12. Are there multiple pathways in the pathogenesis of Huntington's disease?
13. Agregation of huntingtin in neuronal inclusions and dystrophic neurites in brain
14. Oxidative stress, glutamate and neurodegenerative disorders
15. Glutamate and the pathophysiology of hypoxic-ischemic brain damage
16. Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acid
17. Lesion of striatal neurons with kainic acid provides a model for Huntington's chorea
18. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid
19. Replicating Huntington's disease in experimental animals
20. Alternative excitotoxic hypotheses
21. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses?
22. Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced
23. Evidence that the loss of the voltage-dependent Mg++ block at the N-methyl-D-aspartate receptor underlies receptor activation during inhibition of neuronal metabolism
24. Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization
25. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions
26. Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract
27. Evidence for apoptotic cell death in Huntington's disease and excitotoxic animal models
28. Exon 1 of the HD gene with expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice
29. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation
30. Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation
31. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation
32. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene
33. Non linear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and decreases in glutamine and glucose in transgenic Huntington's disease mice
34. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease
35. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration
36. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA
37. Inhibition of caspase 1 slows disease progression in a mouse model of Huntington's disease
38. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease
39. Partial inhibition of brain succinate dehydrogenase by 3-nitropropionic acid is sufficient to initiate striatal degeneration in rat
40. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid
41. Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitropropionate in rats: Implications for neuroprotection studies
42. Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid
43. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates
44. Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease
45. Fetal striatal allografts reverse cognitive deficits in a primate model of Huntington's disease
46. Restoration of cognitive and motor functions by ciliary neurotrophic factor in a primate model of Huntington's disease
47. Serial 1H-NMR spectroscopy study of metabolic impairment in primates chronically treated with the succinate dehydrogenase inhibitor 3-nitropropionic acid
48. Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease
49. Riluzole therapy in Huntington's disease